| Advice You |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Credit > Why Owning a 0% APR Card Could Spell Disaster |
|
Advice You - Why Owning a 0% APR Card Could Spell Disaster
Almost everyone gets the offers in the mail for credit cards that claim to provide 0 percent interest. According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product These offers are incredibly tempting, and on the surface they look like a good idea. You could transfer ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in your outstanding balances, buy that big-ticket item you’ve had your eye on, and get free interest for u lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. to a year. Sounds great, right? Well, beware because there are some hidden pitfalls with these cards t here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe at could spell disaster to your pocketbook and your credit rating. · 0% APR is good for a limited time d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro Most of these credit card offers last for six to nine months, although some are good for up to a year. ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc This means that you can transfer your balances and make purchases for one year with no interest added t easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi your billing statement. However, at the end of this period, you will be charged interest that is calcu nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically ated on your credit score and history, so don’t get lazy and forget to check the calendar. If you buy a and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ big-ticket item near the end of your free interest period, you may end up paying more interest on your ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi redit card than you would have with in-store financing. · 0% APR could be null and void if you make a ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a istake. There are stiff penalties on most of these credit cards that hold you to very high standards. F dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod r example, with some cards, if you are late even one day with your payment, you lose the 0% APR and are cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin immediately moved to a penalty interest rate that can be as high as 24%. · 0% APR could lead you to ou tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen rageously high interest. When the introductory period of free interest is over, you will begin to pay r t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel gular interest on your purchases and any outstanding balances. Be aware, however, that this rate may be ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust much higher than you would get with another standard credit card. The average rates after the introduct y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products ry free interest period is nineteen to twenty-one percent. So if you plan to transfer balances and pay . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de hem all off within a year, then go for it. But remember that if you have a job loss or medical emergenc elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip that keeps you from making a payment, you will be paying outrageously high interest from that point on tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Successful Fundraising Donation Letters Use Before-And-After Samples, Examples
|